Mazda forecasts nearly $1 billion profit hit from U.S. tariffs
To soften the blow of the tariffs, the company said it is taking measures including changing shipping routes, increasing output at its plant in the U.S. state of Alabama and adjusting production volumes.
The impact of the higher U.S. duties on results this year remained "quite significant," assuming that exports from Japan would face a 15% tariff and those from Mexico 25%, Chief Financial Officer Jeffrey Guyton said.
Without its countermeasures, the company would be at risk of a 233.5-billion-yen operating profit hit for the year ending March 2026, Guyton told reporters during a briefing.
Mazda has been trying to boost sales of its CX-50 crossover sport utility vehicle. The company has a major plant in the Mexican state of Guanajuato from where it exports vehicles to the U.S.
It said last week it sold about 210,000 vehicles in the United States over the first half, up 4% from a year earlier.
Mazda has forecast a full-year operating profit of ¥50 billion for the year ending March 2026, down sharply from the previous financial year.
It had previously withheld guidance due to uncertainty surrounding the U.S. tariffs.
($1 = 147.1100 yen)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
2 hours ago
- Reuters
Novavax banks on vaccine supply partnerships to boost 2025 revenue
Aug 6 (Reuters) - Novavax (NVAX.O), opens new tab raised its full-year adjusted revenue forecast on Wednesday, betting on the strength of vaccine supply partnerships, including with Serum Institute of India and Japan's Takeda (4502.T), opens new tab, sending its shares surging 15%. The biotech has been shifting its focus to commercializing vaccine candidates through partnerships. It relies on revenue from its licensing deal with French drugmaker Sanofi ( opens new tab and vaccines in development, including a COVID-flu combination shot and for bird flu that is currently undergoing lab testing. Novavax had licensed the rights for its COVID-19 shot, Nuvaxovid — also its sole commercial product — to Sanofi in an up to $1.2 billion deal last year. The company expects its 2025 adjusted revenue to be between $1 billion and $1.05 billion, up from $975 million to $1.03 billion forecast earlier. This excludes Sanofi sales and royalties. Novavax also beat Wall Street expectations for second-quarter revenue, driven by a $175 million milestone payment related to the U.S. approval of Nuvaxovid in May. It plans to start a post-marketing study on Nuvaxovid by the end of the year, and estimates that to cost between $70 million and $90 million. The company expects Sanofi to reimburse about 70% of the costs, while it will absorb the rest. Novavax's traditional protein-based COVID-19 shot offers an alternative technology to messenger RNA-based rivals from Pfizer (PFE.N), opens new tab and Moderna (MRNA.O), opens new tab, but has failed to make a mark in the U.S. vaccine market due to manufacturing issues and regulatory hurdles. The biotech, however, sees an opportunity after the U.S. Department of Health and Human Services said it would wind down mRNA vaccine development under its biomedical research unit, BARDA, which helps companies develop treatments and diagnostic tools to address public health threats. "There is the potential opportunity for us, particularly since other platforms may be taken out of consideration," Novavax Executive Vice President Silvia Taylor said on a post-earnings call. Novavax said it is working with BARDA on potential funding for its H5N1 bird flu vaccine candidate. It reported total quarterly revenue of $239 million, beating analysts' estimate of $147.96 million, according to data compiled by LSEG. Net income was down 34.4% at $106.51 million.
The Independent
4 hours ago
- The Independent
M&S's viral strawberry sandwich is leaving stores soon – here's my full review
Whether it's a chicken caesar dip, a Dubai-inspired pistachio chocolate bar or premixed cocktail cans, M&S is responsible for plenty of viral food and drink trends. Now, the retail giant has debuted a sandwich reminiscent of a classic British dessert. The stalwart's new strawberries and cream sandwich nods to a signature Japanese sweet treat, known as a fruit sando. The popular snack usually includes fresh fruit, sliced white bread, and fresh whipped cream. The M&S take is made from sweetened brioche bread with the supermarket's famous red diamond strawberries, of which it sells more than 4 million punnets per year. M&S has always been at the forefront of sandwich innovation, having launched the first-ever pre-packed sandwich in the 1980s. Providing a sweet alternative to its cult savoury sandwiches, the £2.80 fruit sando arrived in aisles this week – but will it be a hit in the lunchtime rush? Whether you pack it in your picnic hamper, take it to watch Wimbledon or enjoy it as an afternoon pick-me-up in the office, the new dessert sandwich has landed just in time for summer. Here's everything you need to know, plus my taste test. How we tested I ran to the nearest M&S foodhall to grab the new red diamond strawberry and creme sandwich (it's already selling out across the UK). Considering taste, innovation and value for money, here's the IndyBest verdict.
Reuters
5 hours ago
- Reuters
Novavax raises annual revenue forecast on vaccine supply partnerships
Aug 6 (Reuters) - Novavax (NVAX.O), opens new tab raised its full-year adjusted revenue forecast on Wednesday, banking on higher sales tied to its vaccine supply partnerships, including with South Korea's SK Bioscience ( opens new tab and Japan's Takeda (4502.T), opens new tab. Shares of the biotech were up 4.3% in premarket trading, after it also beat Wall Street expectations for second-quarter revenue, driven by a $175 million milestone payment related to U.S. approval of its COVID-19 shot, Nuvaxovid, in May. Novavax, which is shifting its focus to commercializing vaccine candidates through partnerships, had licensed the rights for Nuvaxovid, its sole commercial product, to French drugmaker Sanofi ( opens new tab in an up to $1.2 billion deal. The company raised its 2025 adjusted revenue forecast to between $1 billion and $1.05 billion, from $975 million to $1.03 billion earlier. This excludes Sanofi sales and royalties. "This quarter we continued to progress our growth strategy," said CEO John Jacobs. "We look forward to continuing to build on this foundation into the second half of the year." Novavax's traditional protein-based COVID-19 shot offers an alternative technology to messenger RNA-based rivals from Pfizer (PFE.N), opens new tab and Moderna (MRNA.O), opens new tab, but has failed to make a mark in the U.S. vaccine market due to manufacturing issues and regulatory hurdles. The biotech said it plans to conduct the post-marketing study on Nuvaxovid requested by the U.S. Food and Drug Administration in 2025 and 2026, and estimates it to cost between $70 million and $90 million. The company expects Sanofi to reimburse about 70% of the costs, while it will absorb the rest. Novavax reported total revenue of $239 million during the quarter, compared with analysts' average estimate of $147.96 million, according to data compiled by LSEG. Net income for the three months ended June 30 came in at $106.51 million, compared with $162.38 million a year earlier.
